Table 1

Demographics of enrolled subjects

CharacteristicsSLEHCP value
N=13N=9
Female, n (%)12 (92.3)8 (88.9)1.000
Age at diagnosis of SLE, years, mean±SD45.9±10.738.3±14.50.182
Immunological profiles
 ANA titre >1:80, n (%)13 (100.0)0 (0.0)
 Anti-SSA/Ro positive, n (%)8 (61.5)
 Anti-SSB/La positive, n (%)2 (15.4)
 Anti-Smith positive, n (%)4 (30.8)
 Anti-RNP positive, n (%)4 (30.8)
 Anti-dsDNA positive, n (%)11 (84.6)
Clinical manifestations
 Haematological disorder, n (%)11 (84.6)
 Kidney involvement, n (%)5 (38.5)
 CNS involvement, n (%)2 (15.4)
 Psychosis, n (%)1 (7.7)
 Serositis, n (%)2 (15.4)
 Joint involvement, n (%)10 (76.9)
 Skin involvement, n (%)11 (84.6)
SLEDAI-2K score, median (range)8 (6–30)
  • CNS, central nervous system; dsDNA, double-stranded DNA; HC, healthy control; RNP, ribonucleoprotein; SLEDAI-2K, SLE Disease Activity Index 2000; SSA/Ro, Sjögren's-syndrome-related antigen A; SSB/La, lupus La protein.